

Resolution

of the Federal Joint Committee on an Amendment of the Pharmaceuticals Directive: Annex XII – Benefit Assessment of Medicinal Products with New Active Ingredients according to Section 35a (SGB V)

Nemolizumab (atopic dermatitis, ≥ 12 years)

of 7 August 2025

At their session on 7 August 2025, the Federal Joint Committee (G-BA) resolved to amend the Pharmaceuticals Directive (AM-RL) in the version dated 18 December 2008 / 22 January 2009 (Federal Gazette, BAnz. No. 49a of 31 March 2009), as last amended by the publication of the resolution of D Month YYYY (Federal Gazette, BAnz AT DD.MM.YYYY BX), as follows:

- I. In Annex XII, the following information shall be added after No. 6 to the information on the benefit assessment of Nemolizumab in the version of the resolution of 7 August 2025 on the therapeutic indication "moderate-to-severe prurigo nodularis":**

Nemolizumab

Resolution of: 7 August 2025

Entry into force on: 7 August 2025

Federal Gazette, BAnz AT DD. MM YYYY Bx

Therapeutic indication (according to the marketing authorisation of 12 February 2025):

Nemluvio is indicated for the treatment of moderate-to-severe atopic dermatitis in patients aged 12 years and older who are candidates for systemic therapy.

Therapeutic indication of the resolution (resolution of 7 August 2025):

See therapeutic indication according to marketing authorisation.

1. Additional benefit of the medicinal product in relation to the appropriate comparator therapy

Adults and adolescents 12 years and older with moderate-to-severe atopic dermatitis who are candidates for systemic therapy

Appropriate comparator therapy:

Dupilumab (in combination with TCS and/or TCI if required)

Extent and probability of the additional benefit of nemolizumab compared to the appropriate comparator therapy:

An additional benefit is not proven.

Study results according to endpoints:¹

Adults and adolescents 12 years and older with moderate-to-severe atopic dermatitis who are candidates for systemic therapy

There are no assessable data.

¹ Data from the dossier assessment of the Institute for Quality and Efficiency in Health Care (IQWiG) (A25-32) unless otherwise indicated.

Summary of results for relevant clinical endpoints

Endpoint category	Direction of effect/ risk of bias	Summary
Mortality	n.a.	There are no assessable data.
Morbidity	n.a.	There are no assessable data.
Health-related quality of life	n.a.	There are no assessable data.
Side effects	n.a.	There are no assessable data.
Explanations: ↑: statistically significant and relevant positive effect with low/unclear reliability of data ↓: statistically significant and relevant negative effect with low/unclear reliability of data ↑↑: statistically significant and relevant positive effect with high reliability of data ↓↓: statistically significant and relevant negative effect with high reliability of data ↔: no statistically significant or relevant difference ∅: No data available. n.a.: not assessable		

2. Number of patients or demarcation of patient groups eligible for treatment

Adults and adolescents 12 years and older with moderate-to-severe atopic dermatitis who are candidates for systemic therapy

Approx. 57,300 to 62,600 patients

3. Requirements for a quality-assured application

The requirements in the product information are to be taken into account. The European Medicines Agency (EMA) provides the contents of the product information (summary of product characteristics, SmPC) for Nemludio (active ingredient: nemolizumab) at the following publicly accessible link (last access: 16 June 2025):

https://www.ema.europa.eu/en/documents/product-information/nemludio-epar-product-information_en.pdf

Treatment with nemolizumab should only be initiated and monitored by specialists who are experienced in the treatment of patients with atopic dermatitis.

4. Treatment costs

Annual treatment costs:

Adults and adolescents 12 years and older with moderate-to-severe atopic dermatitis who are candidates for systemic therapy

Designation of the therapy	Annual treatment costs/ patient
Medicinal product to be assessed:	
Nemolizumab	€ 15,229.63
Appropriate comparator therapy:	
Dupilumab	€ 15,946.67

Costs after deduction of statutory rebates (LAUER-TAXE®) as last revised: 15 July 2025)

Costs for additionally required SHI services: not applicable

5. Designation of medicinal products with new active ingredients according to Section 35a, paragraph 3, sentence 4 SGB V that can be used in a combination therapy with the assessed medicinal product

In the context of the designation of medicinal products with new active ingredients pursuant to Section 35a, paragraph 3, sentence 4 SGB V, the following findings are made:

Adults and adolescents 12 years and older with moderate-to-severe atopic dermatitis who are candidates for systemic therapy

No medicinal product with new active ingredients that can be used in a combination therapy and fulfils the requirements of Section 35a, paragraph 3, sentence 4 SGB V.

The designation of combinations exclusively serves the implementation of the combination discount according to Section 130e SGB V between health insurance funds and pharmaceutical companies. The findings made neither restrict the scope of treatment required to fulfil the medical treatment mandate, nor do they make statements about expediency or economic feasibility.

6. Percentage of study participants at study sites within the scope of SGB V in accordance with Section 35a, paragraph 3, sentence 5 SGB V

The medicinal product Nemluvio is a medicinal product placed on the market from 1 January 2025.

The percentage of study participants in the clinical studies of the medicinal product conducted or commissioned by the pharmaceutical company in the therapeutic indication to be assessed who participated at study sites within the scope of SGB V (German Social Security Code) is ≥ 5 per cent of the total number of study participants.

The clinical studies of the medicinal product in the therapeutic indication to be assessed were therefore conducted to a relevant extent within the scope of SGB V.

II. The resolution will enter into force on the day of its publication on the website of the G-BA on 7 August 2025.

The justification to this resolution will be published on the website of the G-BA at www.g-ba.de.

Berlin, 7 August 2025

Federal Joint Committee (G-BA)
in accordance with Section 91 SGB V
The Chair

Prof. Hecken